Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Bioheart, Inc. (BHRT) Executes Major Financing Agreement

|Includes: Bioheart, Inc. (BHRT)

Located in Sunrise, Florida, Bioheart is a company committed to the discovery, development and commercialization of autologous cell therapies for the treatment of an array of diseases. Today, Bioheart took a major step towards prominence with the announcement they have entered into a $3M standby equity purchase agreement which was previously announced in October.

Bioheart plans to use the proceeds of each of the draws to continue its FDA approved trials with the Florida investor agreeing to purchase $3M of BHRT common stock upon request. The financing agreement is subject to certain conditions, which include the registration of those shares that has been declared effective by the SEC.

Leading the way at Bioheart is Mike Thomas whom serves and the young company’s President and CEO. Thomas stated, “This money gets us that much closer to our end goal of going to market and turning our clinical data into lifesaving procedures. Bioheart has been enrolling patients in clinical trials using stem cells for over 10 years. We are fortunate to have supportive funding partners who allow us to continue development of these products.”

Currently, Bioheart is trading in the $0.08 range. With this new financing agreement in place and an array of technology within the company’s pipeline, Bioheart is a company on the rise.

To learn more about the company as a whole, visit their corporate website at:

Please see disclaimer on the QualityStocks website: